Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02522988 · ClinicalTrials.gov registry record · NA
The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 74
- Enrollment target
NCT02522988 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 74 participants.
The verdict
NCT02522988, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of this randomized-controlled, crossover pilot trial is to evaluate the feasibility, acceptability and effects of a non-deceptive (open-label) administration of placebo pills for treating cancer related fatigue (CRF). If significant effects are found, the investigators will later determine if the presence of a COMT Val18Met genotype variant predicts placebo responses.
Interventions
- BEHAVIORAL Open-label placebo intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2015-06 |
| Est. Completion | 2021-08-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02522988
The ClinicalTrials.gov registry entry for NCT02522988 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Open-label placebo intervention is the first listed.
NCT02522988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02522988 about?
NCT02522988 is a clinical study titled "The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors". The purpose of this randomized-controlled, crossover pilot trial is to evaluate the feasibility, acceptability and effects of a non-deceptive (open-label) administration of placebo pills for treating cancer related fatigue (CRF). If significant effects are found, the investigators will later determi...
What is the current status of trial NCT02522988?
This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2015-06. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT02522988?
The interventions under investigation include: Open-label placebo intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT02522988?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.